https://integramais.com.br/202....4/10/13/8-effective-
The Federal Commerce Commission (FTC) introduced Thursday that it had reached a settlement with Teva Pharmaceutical Industries wherein the corporate will have to pay the agency $1.2 billion over allegations that its Cephalon subsidiary paid generic drugmakers to delay manufacturing of its sleep-disorder drug Provigil. Cephalon owns the patents to both drugs, and presently, neither is on the market in generic type within the U.S. The three circumstances for which Nuvigil is accepted in the
Like
Comment
Share
